DK0777649T3 - N-[2-(pyrrolidinyl-1)-1-phenylethyl]acetamider som kappareceptorantagonister - Google Patents

N-[2-(pyrrolidinyl-1)-1-phenylethyl]acetamider som kappareceptorantagonister

Info

Publication number
DK0777649T3
DK0777649T3 DK95917437T DK95917437T DK0777649T3 DK 0777649 T3 DK0777649 T3 DK 0777649T3 DK 95917437 T DK95917437 T DK 95917437T DK 95917437 T DK95917437 T DK 95917437T DK 0777649 T3 DK0777649 T3 DK 0777649T3
Authority
DK
Denmark
Prior art keywords
pct
unsubstituted
kappar
acetamides
phenylethyl
Prior art date
Application number
DK95917437T
Other languages
Danish (da)
English (en)
Inventor
Fumitaka Ito
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0777649T3 publication Critical patent/DK0777649T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK95917437T 1994-08-24 1995-05-18 N-[2-(pyrrolidinyl-1)-1-phenylethyl]acetamider som kappareceptorantagonister DK0777649T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP1994/001399 WO1996006078A1 (en) 1994-08-24 1994-08-24 N-(2-(pyrrolidinyl-1)-1-phenylethyl)acetamides as kappa receptor antagonists
PCT/IB1995/000374 WO1996006077A1 (en) 1994-08-24 1995-05-18 N-[2-(pyrrolidinyl-1)-1-phenylethyl]acetamides as kappa receptor antagonists

Publications (1)

Publication Number Publication Date
DK0777649T3 true DK0777649T3 (da) 1999-11-29

Family

ID=14098616

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95917437T DK0777649T3 (da) 1994-08-24 1995-05-18 N-[2-(pyrrolidinyl-1)-1-phenylethyl]acetamider som kappareceptorantagonister

Country Status (17)

Country Link
US (1) US5837720A (de)
EP (1) EP0777649B1 (de)
JP (1) JP2935899B2 (de)
AT (1) ATE182138T1 (de)
AU (1) AU2350695A (de)
BR (1) BR9503775A (de)
CA (1) CA2196885C (de)
CO (1) CO4410322A1 (de)
DE (1) DE69510802T2 (de)
DK (1) DK0777649T3 (de)
ES (1) ES2133767T3 (de)
FI (1) FI116056B (de)
GR (1) GR3031133T3 (de)
IL (1) IL114969A0 (de)
MX (1) MX9701367A (de)
TR (1) TR199501055A2 (de)
WO (2) WO1996006078A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
AU7133098A (en) * 1997-04-30 1998-11-24 Warner-Lambert Company Kappa opioid agonists
US5760023A (en) * 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
CA2288828A1 (en) * 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US6284769B1 (en) 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
CA2907921C (en) * 2013-03-22 2021-09-07 Ayumi Pharmaceutical Corporation Inhibition of il-2 production
US9815824B2 (en) 2013-06-28 2017-11-14 Nektar Therapeutics Kappa opioid agonists and uses thereof
CA2937656A1 (en) * 2014-01-24 2015-08-06 Cadila Healtchare Limited Novel heterobicyclic compounds as kappa opioid agonists
AU2016258192B2 (en) 2015-05-06 2021-07-29 Leidos Biomedical Research, Inc. K-Ras modulators
EP3612526A2 (de) * 2017-04-20 2020-02-26 The Regents of the University of California K-ras-modulatoren

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide

Also Published As

Publication number Publication date
JPH09510731A (ja) 1997-10-28
CA2196885C (en) 2001-01-23
ES2133767T3 (es) 1999-09-16
US5837720A (en) 1998-11-17
TR199501055A2 (tr) 1996-07-21
CO4410322A1 (es) 1997-01-09
AU2350695A (en) 1996-03-14
DE69510802T2 (de) 1999-11-04
MX9701367A (es) 1997-05-31
DE69510802D1 (de) 1999-08-19
ATE182138T1 (de) 1999-07-15
FI970746L (fi) 1997-02-21
WO1996006077A1 (en) 1996-02-29
JP2935899B2 (ja) 1999-08-16
FI970746A0 (fi) 1997-02-21
IL114969A0 (en) 1995-12-08
GR3031133T3 (en) 1999-12-31
BR9503775A (pt) 1996-04-16
WO1996006078A1 (en) 1996-02-29
CA2196885A1 (en) 1996-02-29
FI116056B (fi) 2005-09-15
EP0777649A1 (de) 1997-06-11
EP0777649B1 (de) 1999-07-14

Similar Documents

Publication Publication Date Title
DK0777649T3 (da) N-[2-(pyrrolidinyl-1)-1-phenylethyl]acetamider som kappareceptorantagonister
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
DE60120748D1 (de) 3-substituierte oxindolderivate als beta-3-agonisten
JP2004530656A5 (de)
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
JO2239B1 (en) Method for preparing benzothophen derivatives
TR200102839T2 (tr) LH agonistleri olarak faydalı bisiklik heteroaromatik bileşikler.
CA2252895A1 (en) Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
KR950010892A (ko) 자궁 섬유증 억제 방법
BR0108816A (pt) Derivados de quinolina como antagonistas alfa-2
KR950016731A (ko) 지루 및 좌창의 억제 방법
CA2221091A1 (en) Estrogen agonist/antagonists treatment of atherosclerosis
DE60016786D1 (de) Bicyclische vasopressin-agoniste
HRP20010630B1 (hr) Derivati 4-heterociklil-sulfonamidil-6-metoksi-5-(2-metoksi-fenoksi)-2-piridil-pirimidina, njihova proizvodnja i upotreba kao endotelin receptor antagonista
EA200100618A1 (ru) Антагонист витронектинового рецептора
EP0976404A3 (de) Pharmazeutische Zubereitung zur Vorbeugung und Behandlung von kognitiven Störungen bei Säugetieren
SE9802538D0 (sv) New pharmaceutically active compounds
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
ATE318800T1 (de) Indolderivate als mcp-1 rezeptor antagonisten
ATE101599T1 (de) Muscarin-rezeptor-antagonisten.
KR940005581A (ko) 안지오텐신 ii 길항물질
MX9701529A (es) Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos.
AU6300396A (en) Use of phenoxy pyridine derivatives for the treatment of ill nesses caused by disorders of the dopamine system
RU96120197A (ru) Применение производных тиокетена для предотвращения или лечения гепатита в